Area of research
Endocrinology, Diabetes and Metabolism · Oncology
Research interest
Research interests include Medicine, Internal medicine, Placebo, Clinical endpoint, Thyroid carcinoma, and Oncology.
Understanding and overcoming multidrug resistance in cancer
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer
Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.
LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): A subgroup analysis based on the ALTER01031 trial.
Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).
Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.
First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial
2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
Whole exome sequencing identifies lncRNA<i>GAS8-AS1</i>and<i>LPAR4</i>as novel papillary thyroid carcinoma driver alternations